MedTrace Logo

Grazax Asthma Prevention

NCT01061203 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 812

Last updated 2016-09-08

No results posted yet for this study

Summary

Investigation of the effect of Grazax (grass tablet) on asthma prevention in children with grass pollen allergy

Conditions

  • Allergic Rhinitis

Interventions

DRUG

Grazax

Treatment with 75.000 SQ-T once daily

DRUG

Placebo

Tablet with no active grass component.

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Erkka Valovirta, MD · Terveystalo Turku, Finland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01061203 on ClinicalTrials.gov